The cellular components of the hematopoietic stem cell niche have been gradually identified. However, the niche for malignant hematopoiesis remains to be elucidated. Here, using human leukemia cells, which could be transplanted to immunodeficient mice, we studied the in vivo homing, proliferation and survival sites by immunohistopathology, compared with the corresponding sites for cord blood CD34 þ (CBCD34 þ ) cells. The human leukemia cells initially localized on the surface of osteoblasts in the epiphysial region, and expanded to the inner vascular and diaphysial regions within 4 weeks. The percentage of CD34 þ leukemia cells in the bone marrow was transiently increased up to 50%. In vivo 5-bromo-2 0 -deoxyuridine labeling revealed that the epiphysis was the most active site for leukemia cell proliferation. CBCD34 þ cells showed the similar pattern of homing and proliferation to leukemia cells. After high-dose administration of cytosine-1-b-D-arabinofuranoside, residual leukemia cells were localized in the perivascular endothelium as well as in contact with the trabecular endosteum. These findings suggest that xenotransplantation into immunodeficient mice provides a useful model to study the leukemia niche.
Introduction
Bone marrow (BM) is the major site of adult hematopoiesis. In particular, the maintenance of hematopoietic stem cells (HSCs) needs a specialized microenvironment called the 'niche' in the BM. [1] [2] [3] Various cellular components such as osteoblasts, 4, 5, 7 endothelial cells 6 and adipocytes 7, 8 have been reported to support hematopoiesis. 9 Studies to trace transplanted HSCs show that BM HSCs reside close to the endosteal surface in the trabecula, and that hematopoietic differentiation proceeds readily toward the longitudinal axis of the marrow. 3, [10] [11] [12] Recently, some types of osteoblasts were reported to act as niche cells. 4, 7, 9 Although the mechanism to maintain HSCs remains unclear, N-cadherin, Notch-1/Jagged-1, osteopontin (OPN), vascular endothelial growth factor (VEGF) and Tie2/Ang-1 signaling pathways have been suggested to be involved in the self-renewal, antiapoptosis and quiescence of HSCs. 4, 5, 7, [12] [13] [14] [15] [16] [17] Similar to normal hematopoiesis, leukemia has also been recognized to be maintained by a fraction of leukemia cells. [18] [19] [20] Intravenous injection of human leukemia cells into non-obese diabetes/severe combined immunodeficiency (NOD/SCID) mice, which is now the most common and most nearly physiological method to identify human HSCs in vivo, shows that leukemia cells expressing primitive cell surface makers such as CD34
þ and CD38 À can repopulate NOD/SCID mice regardless of the acute myeloid leukemia (AML) type. [21] [22] [23] The concept of leukemia stem cells (LSCs) may change current notions about how leukemia develops and how leukemia should be treated. However, the microenvironment for LSC is not yet well understood. Prior studies have characterized the impact of VEGF signals and CXCR4/stromal-derived factor 1 (SDF1) interaction on homing, engraftment and survival of leukemia cells in NOD/SCID mice. 24, 25 To elucidate the cellular niche, we analyzed here the spatial localization of transplanted human leukemia cells into immunodeficient mice. First, we identified human leukemia samples that could be efficiently engrafted and passed from mice to mice. Using these leukemia samples, we then examined the homing, proliferation and survival sites of leukemia cells by immunohistopathology, in comparison with the corresponding sites for CD34 þ cord blood mononuclear cells (CBMNCs) and human leukemia cell lines.
Materials and methods

Cells
BM cells from acute leukemia patients were collected after obtaining informed consent. BM mononuclear cells were separated by Ficoll-paque PLUS (Amersham Bioscience, Uppsala, Sweden) density-gradient centrifugation and suspended in Rosewell Park Memorial Institute 1640 medium (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Gibco-BRL), 100 IU/ml of penicillin G (Meiji Seika, Tokyo, Japan) and 100 mg/ml of streptomycin (Meiji Seika).
The MAS cells were derived from a 34-year-old Japanese female patient with AML M0. The original leukemia cells were positive for CD13, 33 and 7, and negative for myeloperoxidase (MPO), and CD3, CD4, CD5, CD10, CD11b, CD14, CD19, CD34, CD41a, CD41b and CD56. The karyotype was 46,XX,t(11;19)(q23;p13),add(12)(p11), and molecular analysis showed the presence of a MLL/ENL fusion gene. The SUG cells were derived from a 54-year-old Japanese patient with pre-T acute lymphoblastic leukemia. They were positive for CD3, CD5, CD7, CD99 and terminal deoxynucleotidyl transferase, and negative for MPO, and CD4, CD8, CD34 and CD56. The karyotype was 46,XY,del(1)(p13;p22). A SIL/TAL1 fusion gene was not detected. Both the samples were harvested from BM at relapse and contained more than 90% of leukemia cells.
Cord 
Flow-cytometric analyses
Samples were analyzed with a FACScalibur (BD), according to the manufacturer's directions. Briefly, cells were mixed and incubated with appropriate volumes of antibodies for 30 min on ice. These cells were examined by staining with a combination of PerCP-conjugated anti-human CD45 antibody (BD, San Jose, CA, USA) for the CD45 gate, and PE-conjugated antibody and/or fluorescein isothiocyanate (FITC)-conjugated antibody. The PEconjugated antibodies used were: anti-human CD3, CD5, CD10, CD13, CD33, CD34 and CD41 antibodies (BD). The FITC-conjugated antibodies used were anti-human CD4, CD7, CD14, CD19 and CD34 antibodies (BD). An additional reaction with FITC-, PE-and PerCP-labeled isotype control antibodies (BD) was performed as a negative control. Analyses were performed using CELL Quest software (BD).
Pathological examination
The mice were killed after ether anesthesia, and organs were fixed in 3.7% formalin (Sigma, St Louis, MO, USA) for 24 h. The sternum, tibia and femur were decalcified in phosphate-buffered formalin (3.7% formalin, pH 7.4) containing 20% ethylenediaminetetraacetic acid (Sigma) for 48 h, before paraffin embedding. Tissues were treated with standard methods using ethanol and xylene series. Sections (4 mm) were mounted on slides and treated with standard methods using xylene and ethanol series. The deparaffinized sections were stained with hematoxylin and eosin. For immunohistochemical staining of human CD45, endogenous peroxidase was blocked in all tissues with 3% H 2 O 2 in methanol. All tissue sections were pretreated in a microwave oven in citrate buffer at pH 6.0 for 10 min at 1001C at 300 W and processed using a LSAB2 system (DAKO Cytomation, Kyoto, Japan) employing anti-human CD45 mouse monoclonal antibody (DAKO Cytomation) and anti-human CD34 monoclonal antibody (DAKO Cytomation) according to the instructions of the automatic immunohistochemical stainer (DAKO Cytomation). Counterstaining of 3,3 0 -diaminobenzidine tetrahydrochloride was performed using hematoxylin. To clarify if the sites of survival of human leukemia cells in the BM after chemotherapy are related to vascular region, dual immunohistochemistry was also performed combining anti-CD45 monoclonal antibody (Dako, Tokyo, Japan) with anti-tissue transglutaminase antibody (CUB 742; Dako, Tokyo, Japan). 27 Reactivity for CD45 was detected using the Ventanaenhanced alkaline phosphatase red detection kit. After washing in phosphate-buffered saline (pH 7.5) three times, staining for tissue transglutaminase was performed using a streptavidin biotin peroxidase linking system and diaminobenzidine as the chromogen with counterstaining.
Fluorescent immunohistochemical staining of bone section
For fluorescent immunohistochemical staining, we prepared undecalcified bone section. Freshly isolated femur was embedded in optimal cutting temperature (OCT) medium and frozen in cooled 2-methylbutane using 2-methylbutane (Sigma) and liquid nitrogen. Frozen sections (4 mm) were obtained using cryostat (MICROME, model HM505) equipped with a tungsten carbide knife. The procedure for immunohistochemistry of bone sections was as described previously. 17 In brief, after an overnight incubation at 41C with anti-OPN Ab (P-18, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), slides were stained with anti-goat IgG-Alexa 488 (Molecular Probes, Eugene, OR, USA). Then, bone sections were incubated with ant-hCD45 (HI30, BD Bioscience, San Jose, CA, USA). After incubation with anti-hCD45 Ab, bone sections were stained with anti-mouse IgG-Alexa546 (Molecular Probes). For nuclear staining, samples were treated with TOTO3 (Molecular Probes). Fluorescence images were obtained using confocal laser scanning (FluoView FV1000, OLYMPAS).
Detection of 5-bromo-2
0 -deoxyuridine þ cells BM cells collected from the mice transplanted with MAS or SUG cells were subjected to multicolor cytometric analysis using PE-conjugated anti-human CD34 antibody (BD) and an FITC 5-bromo-2 0 -deoxyuridine (BrdU) Flow Kit (BD) according to the manufacturer's protocol. In vivo BrdU labeling was performed as follows. Ten million MAS or SUG leukemia cells were passed into NOG mice via a tail vein. The mice were injected with 0.2 ml of BrdU (5 mg/ml, Sigma) intraperitoneally three times at 4, 24 and 48 h before killing on day 14 or 28 after transplantation, and immunohistochemical staining of BrdU was performed using a BrdU staining kit (Zymed, San Francisco, CA, USA) according to the manufacturer's protocol.
Cytosine-1-b-D-arabinofuranoside treatment
Mice transplanted with MAS or MOLM13 cells were injected with 0.2 ml of cytosine-1-b-D-arabinofuranoside (Ara-C) (200 mg/ml, Sigma) intraperitoneally twice at 24 and 48 h before killing on day 14 or 28 after transplantation, and subjected to pathological examination.
Statistics
The level of significance was calculated using the Student's t-test.
Results
Phenotypes of leukemia cells used in this study
We injected leukemia cells from a total of 25 patients into NOG mice. At the 8th week, human CD45 þ cells accounted for more than 50% of BM or spleen cells in mice injected with two of the 25 patients' samples. In the two samples, the cell markers and karyotypes were similar to the original samples (Table 1 ). Both leukemias have been maintained in vivo in mice by passage for over 2 years. We named these leukemias MAS and SUG, respectively. MAS and SUG cells after two or three passages were used for the following experiments.
Homing or lodging of human leukemia cells, CBCD34 þ cells and cell lines in NOG mice Two weeks after transplantation, MAS and SUG cells were detected on the inner bone membrane of the epiphysial trabecula ( Figure 1 ). Although CD34 was dully expressed in these cells before transplantation, it was positively stained in MAS and SUG cells transplanted in vivo (Figure 1 ). At 4 weeks, MAS and SUG cells were found in the lumen of the BM as well as on the inner bone membrane, and nearly 30% of the cells were positive for CD34. Significantly more leukemia cells were detected in the epiphysis than in the diaphysis. In the mice transplanted with CBCD34 þ cells, human CD45 þ cells homed and proliferated in similar regions to the MAS and SUG cells. However, only about 1% of the CB cells were CD34 þ , and they were detected in contact with the inner bone membrane (Figure 1) .
To investigate the homing site of leukemia cell lines, we injected three myeloid cell lines, KG-1, NB4 and MOLM13, into NOG mice via a tail vein. Among the leukemia cell lines we examined, MOLM13 was detected in both endosteal and perivascular regions (Supplementary Figure A) . Whereas KG-1 and NB4 were detected mainly in the perivascular region (data not shown), these cell lines were found to home equally efficiently to the epiphysial and diaphysial regions (Supplementary Figure A) . These findings indicate that the homing site of primary leukemia cells might be the same as that of normal HSCs, and that the expression of CD34 is differently regulated between leukemia cells and normal HSCs. Furthermore, leukemia cell lines were shown to localize in mice in manners different from primary leukemia cells.
Direct contact of MAS cells with osteoblasts
To study whether human leukemia cells directly contact osteoblasts, we transplanted MAS cells (1 Â 10 7 cells) and performed two-color immunostaining by confocal laser scanning microscopy on day 3. Direct interaction between CD45 þ cells and OPN þ osteoblasts in the BM trabecula was observed in the epiphysis of NOG mice (Figure 2 ).
Expression of CD34 in MAS and SUG cells transplanted into mice
As shown in Figure 1 , CD34 was expressed in MAS and SUG cells transplanted into NOG mice, although it was not expressed in these cells significantly before transplantation. We examined the time course of CD34 expression by flow-cytometric analyses during 16 weeks after transplantation (Figure 3 ). The percentage of MAS cells expressing CD34 was increased to 50% at 2 and 4 weeks, whereas 40% of SUG cells were positive at 4 and 8 weeks. At 8 or 16 weeks, the expression levels decreased to the initial levels.
In vivo BrdU labeling
To clarify the site of proliferation of leukemia cells in vivo, we injected BrdU intraperitoneally and labeled MAS cells for 48 h. BrdU þ MAS cells were detected mainly in the epiphysial regions, and less frequently in the diaphysial regions (Figure 4) . In other organs, BrdU þ MAS cells were rarely observed throughout the experiment (Supplementary Figure B) . In Table 1 Comparison of cell markers and karyotypes between original and engrafted cells 
Localization and kinetics of leukemia cells in vivo
M Ninomiya et al contrast, BrdU þ MOLM13 cells were localized in the periendothelial region and were more abundant in the diaphysis than in the epiphysis (Figure 4 ). These data suggest that the proliferation sites are different between primary leukemia cells and cell lines.
Sites of residual leukemia cells in the BM after Ara-C treatment
We then hypothesized that the sites of residual leukemia cells after chemotherapy would correspond to the leukemia niche. The transplanted mice were administered 40 mg Ara-C twice 24 and 48 h before killing. In the epiphysis, residual leukemia was observed in the vascular region as well as in the endosteal region ( Figure 5, Supplementary Figure C) . On the other hand, it was found exclusively in the vascular region of the diaphysis. It was further confirmed that the residual leukemia cells were localized on the perivasucular endothelium by the dual immunostaining of CD45 and tissue transglutaminase, a marker of blood vessels (Figure 5b ). After Ara-C treatment, MOLM13 was also found in the periendothelial region of the BM.
Discussion
In this study, we analyzed the localization and kinetics of human leukemia cells in NOG mice. NOG mice are more Localization and kinetics of leukemia cells in vivo M Ninomiya et al severely immunodeficient than NOD/SCID mice regarding the impairment of macrophage and NK activities. 26 The advantages of NOG mice are that they show higher rates of engraftment of human HSCs and of myeloid/lymphoid reconstitution after transplantation of CBCD34 þ cells. [26] [27] [28] [29] [30] Before transplantation, we did not use DNA-damaging agents or radiation, which increase the production of chemokines and potentially expand the niche for HSCs and leukemia cells. In the early phase of 'primary leukemia cells' transplantation, we observed human leukemia cells not only on the surface of osteoblasts but also in the region adhering to vascular endothelia within a few days after transplantation. However, the proliferation always occurred on the surface of osteoblasts at 1 or 2 weeks. At that time, however, it was difficult to determine whether these CD45 Localization and kinetics of leukemia cells in vivo M Ninomiya et al cells were of leukemia origin or not. During passage of human hematopoietic cells through NOG mice, self-renewal leukemia cells might be enriched, which enabled us to clearly identify the location of leukemia niche. In transplantation of leukemia samples from 25 patients, we finally established two leukemia 'vivo lines', which could be successfully transplanted and maintained by passage from non-irradiated NOG mouse to mouse. Although these did not survive and proliferate in culture as cell lines, only MAS cells could be cultured ex vivo in co-culture with HESS-5 (data not shown).
In contrast to MAS and SUG cells, conventional leukemia cell lines such as MOLM13, KG1 and NB4 did not necessarily home to the osteoblasts but to the perivascular regions in the BM. They lodged and proliferated in the diaphysis as well as in the epiphysis, and further in the spleen, liver and kidney. These findings suggest the biological difference between primary cells and cell lines of leukemia, and teach the importance to establish 'vivo-dependent' leukemia lines for the research of leukemia in vivo.
To examine whether the detection of human CD45 by immunohistochemistry could identify the homing or lodging sites of normal HSCs, we transplanted CD34
þ CBMNCs into non-irradiated NOG mice and immunostained human CD34 and CD45. After 2 weeks, CD34
þ /CD45 þ cells were identified in contact with osteoblasts in the endosteal lumen, and thereafter CD34
À /CD45 þ cells proliferated in the inner vascular region. These observations clearly indicate that human HSCs home or lodge at the murine hematopoietic niche in the early phase of transplantation, which supports that our experiment system is valid for looking a 'leukemia niche'.
In this study, we showed that osteoblasts serve as niche for MAS and SUG leukemia cells. Although the homing process is not fully understood, SDF-1, which is produced by BM stromal and endothelial cells, has been reported to play an important role. [31] [32] [33] As human and mouse SDF-1 are crossreactive, SDF-1 must be potentially involved in the LSC homing. However, MAS express a low level of CXCR4, a receptor of SDF-1, on the cell surface, and MAS cells did not migrate toward the SDF-1 axis using EZ-TAXIScan (data not shown). As intracytoplasmic CXCR4 was detected, CXCR4 might be upregulated in vivo by hypoxia. Mechanism other than SDF1-CXCR4 may be associated with the homing of MAS cells to osteoblasts. We also showed that the epiphysial region was a more active site for homing and proliferation than the diaphysial region. This is not simply explained by the blood flow, because in the case of MOLM13 there was no preference for the epiphysial compared to the diaphysial region. Recently, a gradient of the VEGF concentration was reported from the epiphysis to the diaphysis. 34 VEGF receptor 1 (VEGFR1) and VLA-4 was also reported to regulate organ-specific tumor metastasis. 35 As VEGFR1 and VEGFR2 were expressed in MAS and SUG cells, VEGF may be one of the important factors regulating the localization. Molecular mechanism of homing to the niche would be further clarified using this transplantation system.
Next, we showed that the expression of CD34 was increased along with the proliferation of the leukemia cells. CD34 has been long believed to be an HSC marker, but recent data revealed that the expression of CD34 is reversible and regulated by HSC activation. 22, 23 Although the functional significance of CD34 remains unclear, L-selectin on leukocytes and E-selectin on vascular endothelium are putative ligands of CD34. [36] [37] [38] Our preliminary data showed both the CD34 þ and CD34 À fractions of SUG cells could similarly reconstitute leukemia in NOG mice. This transplantation model might provide new insight into the regulation of CD34 expression in leukemia cells.
The proliferation sites of leukemia cells were mainly the epiphysial region rather than the diaphysial region. Furthermore, the proliferating cells detected by the incorporation of BrdU were found in all parts of the epiphysial region. There are several reports suggesting the advantages of the epiphysis as a stem cell niche, 3, [9] [10] [11] but the details of the function of the niche remain unclear. The anatomical structure of trabecular bone or factors present there may be suitable for the niche. From the clinical point of view, joint pain in leukemia patients may be caused by the marked proliferation of leukemia cells in the epiphysis.
It has been unclear where leukemia cells survive after chemotherapy. After high-dose treatment with Ara-C, leukemia cells in this study were clustered and adhered to the blood vessels as well as to the endosteum. The residual cells were equally observed in the epiphysis and diaphysis, suggesting that leukemia cells receive antiapoptotic signals not only from osteoblasts but also vascular endothelium. Finally, we postulate that our model would be useful not only to understand the mechanisms underlying residual leukemia but also to develop new therapies for human leukemia.
